ARCELLX INC's ticker is and the CUSIP is 03940C100. A total of 50 filers reported holding ARCELLX INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 1.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,937,376 | -83.5% | 53,996 | -85.5% | 0.00% | -100.0% |
| Q2 2023 | $11,755,526 | -75.1% | 371,775 | -75.7% | 0.00% | -80.0% |
| Q1 2023 | $47,203,878 | -12.0% | 1,532,096 | -11.5% | 0.01% | -16.7% |
| Q4 2022 | $53,614,174 | +61.8% | 1,730,606 | -2.0% | 0.01% | +71.4% |
| Q3 2022 | $33,136,000 | +5.8% | 1,765,370 | -0.2% | 0.01% | -12.5% |
| Q2 2022 | $31,333,000 | +74.2% | 1,769,400 | +34.1% | 0.01% | +100.0% |
| Q1 2022 | $17,983,000 | – | 1,319,026 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LP | 5,500,007 | $169,455,216 | 63.12% |
| NEA Management Company, LLC | 4,745,262 | $146,201,522 | 10.11% |
| Samsara BioCapital, LLC | 909,579 | $28,024,129 | 5.79% |
| Paradigm Biocapital Advisors LP | 1,757,779 | $54,157,171 | 5.13% |
| Soleus Capital Management, L.P. | 1,248,147 | $38,455,409 | 3.98% |
| Perceptive Advisors | 3,841,739 | $118,363,979 | 3.50% |
| Cormorant Asset Management, LP | 1,600,000 | $49,296 | 3.25% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,398,321 | $73,892,270 | 3.12% |
| Altium Capital Management LP | 150,000 | $4,621,500 | 2.56% |
| Novo Holdings A/S | 1,225,000 | $37,742,250 | 2.49% |